[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS]

Arerugi. 2020;69(3):213-217. doi: 10.15036/arerugi.69.213.
[Article in Japanese]

Abstract

Background: Prurigo nodularis is a chronic disease characterized by a hard dome-like or wart-like nodule which is solitary and does not fuse. Prurigo nodularis presents as one of the symptoms of atopic Dermatitis (AD).

Cases: We present three cases of AD children with intractable prurigo nodularis. 1) a 9-Year-Old Boy, 2) an 11-Year-Old Girl, and 3) an 8-Year-Old Boy. The Eczema Area and Severity Index (EASI) in the first visit was 27.7, 30.6, and 49.0, respectively. All patients had been treated with very strong or strongest potency topical steroids for 3-9 years. Quality of life (QOL) had declined due to severe pruritus, and they had striae and secondary adrenal suppression as side effects of steroids. Case 1 and 2 were treated with Cyclosporine A (CyA), case 3 was treated with Duplimab when he was 15 years old; all patients improved.

Discussion: CyA and Duplimab are not indicated for children in Japan, however, it is necessary to consider not only topical medicine but also other additional treatments when faced with adrenal suppression as a side effect of steroids or loss of QOL.

Conclusion: CyA and Duplimab, that were effective in AD with intractable prurigo nodularis, are expected to become indications for AD children.

Keywords: atopic dermatitis; children; cyclosporine A; dupilumab; prurigo nodularis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Cyclosporine / therapeutic use
  • Dermatitis, Atopic / complications
  • Dermatitis, Atopic / drug therapy*
  • Female
  • Humans
  • Japan
  • Male
  • Prurigo / complications
  • Prurigo / drug therapy*
  • Quality of Life

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab
  • Cyclosporine